title: Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells.
abstract: The NF-κB is best known for its role in inflammation. Here we show that constitutive NF-κB activity in cancer cells promotes the biosynthesis of redox scavenger glutathione (GSH), which in turn confers resistance to oxidative stress. Inhibition of NF-κB significantly decreases GSH in several lines of human leukemia and prostate cancer cells possessing high or moderate NF-κB activities. Concomitantly, NF-κB inhibition by pharmacological and molecular means sensitizes "NF-κB positive" cancer cells to chemically-induced oxidative stress and death. We propose that inhibition of NF-κB can reduce intracellular GSH in "NF-κB-positive" cancers thereby improving the efficacy of oxidative stress-based anti-cancer therapy.
authors.affiliation: Department of Environmental Health, University of Cincinnati, College of Medicine, Cincinnati, OH 45267, United States.
authors.forename: Qinghang
authors.initials: Q
authors.lastname: Meng
authors.forename: Zhimin
authors.initials: Z
authors.lastname: Peng
authors.forename: Liang
authors.initials: L
authors.lastname: Chen
authors.forename: Jutong
authors.initials: J
authors.lastname: Si
authors.forename: Zhongyun
authors.initials: Z
authors.lastname: Dong
authors.forename: Ying
authors.initials: Y
authors.lastname: Xia
mesh_terms: D000818:Animals; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology; D005978:Glutathione / Q000378:metabolism*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D051379:Mice; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology*; D018384:Oxidative Stress; D010087:Oxides / Q000494:pharmacology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D015398:Signal Transduction
chemical_list: D001152:Arsenicals; D016328:NF-kappa B; D010087:Oxides; D005978:Glutathione; D000077237:Arsenic Trioxide
references.citation: Cancer Res. 2000 Oct 1;60(19):5334-9
references.pmid: 11034066
references.citation: Semin Hematol. 2002 Apr;39(2 Suppl 1):3-7
references.pmid: 12012315
references.citation: Biochem J. 2001 Jul 15;357(Pt 2):447-55
references.pmid: 11439094
references.citation: Leuk Lymphoma. 2007 Jun;48(6):1187-99
references.pmid: 17577783
references.citation: J Clin Invest. 2005 Oct;115(10):2625-32
references.pmid: 16200195
references.citation: Ann N Y Acad Sci. 2004 Dec;1030:569-77
references.pmid: 15659839
references.citation: Oncogene. 1999 Dec 2;18(51):7389-94
references.pmid: 10602496
references.citation: Nat Rev Immunol. 2005 Oct;5(10):749-59
references.pmid: 16175180
references.citation: Cell. 2004 Nov 12;119(4):529-42
references.pmid: 15537542
references.citation: Oncologist. 2001;6 Suppl 2:11-6
references.pmid: 11331435
references.citation: Carcinogenesis. 1994 Jul;15(7):1301-7
references.pmid: 7913422
references.citation: Ann N Y Acad Sci. 2004 Dec;1030:434-41
references.pmid: 15659827
references.citation: Mol Cell Biol. 1990 May;10(5):2154-63
references.pmid: 1970118
references.citation: Br J Cancer. 1997;76(2):206-10
references.pmid: 9231920
references.citation: Acta Pharmacol Sin. 2007 Sep;28(9):1434-49
references.pmid: 17723177
references.citation: Blood. 1999 Sep 15;94(6):2102-11
references.pmid: 10477740
references.citation: Free Radic Biol Med. 2004 Nov 15;37(10):1511-26
references.pmid: 15477003
references.citation: Hum Pathol. 2004 Feb;35(2):246-53
references.pmid: 14991544
references.citation: Oncogene. 1999 Nov 22;18(49):6853-66
references.pmid: 10602461
references.citation: Biochem Biophys Res Commun. 2001 Jul 13;285(2):476-82
references.pmid: 11444867
references.citation: Cell Death Differ. 2006 May;13(5):738-47
references.pmid: 16485028
references.citation: Annu Rev Biochem. 1983;52:711-60
references.pmid: 6137189
references.citation: J Natl Cancer Inst. 1992 Jun 17;84(12):951-7
references.pmid: 1378502
references.citation: Mol Pharmacol. 2010 May;77(5):784-92
references.pmid: 20159942
references.citation: Blood. 2005 Dec 1;106(12):3917-25
references.pmid: 16105982
references.citation: Leukemia. 2004 Jan;18(1):103-12
references.pmid: 14574326
references.citation: J Biol Chem. 2007 Jul 20;282(29):21487-96
references.pmid: 17526490
references.citation: Chem Biol Interact. 1998 Apr 24;111-112:1-14
references.pmid: 9679538
references.citation: Mol Cell Biol. 1999 Aug;19(8):5785-99
references.pmid: 10409765
references.citation: J Biol Chem. 2009 Jan 30;284(5):2657-2671
references.pmid: 19047049
references.citation: Expert Opin Ther Targets. 2007 Feb;11(2):133-44
references.pmid: 17227230
references.citation: Leuk Res. 2009 May;33(5):710-6
references.pmid: 18977528
references.citation: Prostate. 2002 Aug 1;52(3):183-200
references.pmid: 12111695
references.citation: Cancer Res. 2003 Nov 15;63(22):7689-93
references.pmid: 14633691
references.citation: Hematology Am Soc Hematol Educ Program. 2003;:1-13
references.pmid: 14633774
references.citation: Nature. 2000 Apr 13;404(6779):778-82
references.pmid: 10783893
references.citation: J Cell Sci. 2002 Jan 1;115(Pt 1):141-51
references.pmid: 11801732
references.citation: Nature. 2004 Sep 23;431(7007):461-6
references.pmid: 15329734
references.citation: Cancer Lett. 2009 Feb 8;274(1):132-42
references.pmid: 18952368
references.citation: Anal Biochem. 2000 Apr 10;280(1):80-6
references.pmid: 10805524
references.citation: Drug Resist Updat. 2004 Feb;7(1):53-67
references.pmid: 15072771
references.citation: Blood. 2001 Oct 15;98(8):2301-7
references.pmid: 11588023